{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:53:29Z","timestamp":1790902409720,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.bbrc.2009.12.086","type":"journal-article","created":{"date-parts":[[2009,12,22]],"date-time":"2009-12-22T04:08:13Z","timestamp":1261454893000},"page":"1610-1615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Blockade of the ERK or PI3K\u2013Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib"],"prefix":"10.1016","volume":"391","author":[{"given":"Kei-ichi","family":"Ozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohsuke","family":"Fujio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Tanimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2009.12.086_bib1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1146\/annurev.bi.54.070185.004341","article-title":"Protein-tyrosine kinases","volume":"54","author":"Hunter","year":"1985","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbrc.2009.12.086_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signaling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2009.12.086_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2009.12.086_bib4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph\u2019 translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2009.12.086_bib5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2009.12.086_bib6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrc1506","article-title":"Gefitinib \u2013 a novel targeted approach to treating cancer","volume":"4","author":"Herbst","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2009.12.086_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10147-007-0699-1","article-title":"The Bcr\u2013Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias","volume":"12","author":"Maekawa","year":"2007","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2009.12.086_bib8","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2005.08.409","article-title":"Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer","volume":"23","author":"Giaccone","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2009.12.086_bib9","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2009.12.086_bib10","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2009.12.086_bib11","first-page":"225","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.bbrc.2009.12.086_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR\u2013ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2009.12.086_bib13","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.bbrc.2005.11.131","article-title":"Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death","volume":"339","author":"Ozaki","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2009.12.086_bib14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0006-291X(03)00670-3","article-title":"Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: downregulation of matrix metalloproteinase-3\/-9\/-14 and CD44","volume":"304","author":"Tanimura","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2009.12.086_bib15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.onc.1202367","article-title":"Constitutive activation of the 41-\/43-kDa mitogen-activated protein kinase signaling pathway in human tumors","volume":"18","author":"Hoshino","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2009.12.086_bib16","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr\u2013Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2009.12.086_bib17","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1074\/jbc.M006132200","article-title":"Blockade of the extracellular signal-regulated kinase pathway induces marked G1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated: up-regulation of p27Kip1","volume":"276","author":"Hoshino","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2009.12.086_bib18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1349-7006.2007.00669.x","article-title":"Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs","volume":"99","author":"Ozaki","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbrc.2009.12.086_bib19","doi-asserted-by":"crossref","first-page":"26503","DOI":"10.1074\/jbc.274.37.26503","article-title":"Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2","volume":"274","author":"Iwasaki","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2009.12.086_bib20","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1242\/jcs.02711","article-title":"Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian sprouty isoforms","volume":"118","author":"Ozaki","year":"2005","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbrc.2009.12.086_bib21","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2009.12.086_bib22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/07853890600551037","article-title":"Targeting the ERK signaling pathway in cancer therapy","volume":"38","author":"Kohno","year":"2006","journal-title":"Ann. Med."},{"key":"10.1016\/j.bbrc.2009.12.086_bib23","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-09-0317","article-title":"In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models","volume":"15","author":"Hoeflich","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2009.12.086_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1042\/bj3330291","article-title":"The cellular response to oxidative stress; influences of mitogen-activated protein kinase signaling pathways on cell survival","volume":"333","author":"Wang","year":"1999","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2009.12.086_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0014-5793(03)00517-9","article-title":"PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells","volume":"546","author":"Nakaso","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbrc.2009.12.086_bib26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.bbrc.2008.11.109","article-title":"Blockade of constitutively activated ERK signaling enhances cytotoxicity of microtubule-destabilizing agents in tumor cells","volume":"378","author":"Tanimura","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2009.12.086_bib27","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-06-0639","article-title":"Blockade of the phosphatidylinositol-3-kinas\u2013Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated","volume":"6","author":"Fujiwara","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbrc.2009.12.086_bib28","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1158\/0008-5472.CAN-08-3786","article-title":"Is anticancer drug development heading in the right direction?","volume":"69","author":"Hambley","year":"2009","journal-title":"Cancer Res."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X09024590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X09024590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T10:46:40Z","timestamp":1757760400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X09024590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0006291X09024590"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2009.12.086","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blockade of the ERK or PI3K\u2013Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2009.12.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}